Search results
Within the group of people with oligodendroglioma, IDH-mutant, 1p19q codeleted, CNS WHO grade 2, initial therapy may be deferred until radiographic or symptomatic progression in some people with positive prognostic factors (eg, complete resection and younger age) or concerns about toxicity.
- Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme
All patients had died at the time of analysis. Overall...
- JCO Oncology Practice
JCO PO Article Insights: Talazoparib in Solid Tumors with...
- PDF
States are newly diagnosed with diffuse astrocytic and...
- CCNU
High-risk low-grade glioma patients harboring IDH wild-type...
- Randomized Trial of Procarbazine, Lomustine, and Vincristine in The Adjuvant Treatment of High-Grade Astrocytoma
PATIENTS AND METHODS: After surgery, patients aged ≤ 70...
- Randomized Phase II Study of Temozolomide and Radiotherapy Compared With Radiotherapy Alone in Newly Diagnosed Glioblastoma Multiforme
Median time to progression was 10.8 months in group A and...
- Export Citation
Chętnie wyświetlilibyśmy opis, ale witryna, którą oglądasz,...
- Track Citation
Chętnie wyświetlilibyśmy opis, ale witryna, którą oglądasz,...
- Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme
The present paper reviews astrocyte pathology in major depressive disorder (MDD) and proposes that reductions in astrocytes and related markers are key features in the pathology of MDD.
C71.9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2025 edition of ICD-10-CM C71.9 became effective on October 1, 2024. This is the American ICD-10-CM version of C71.9 - other international versions of ICD-10 C71.9 may differ.
Multiple brain regions from individuals with major depressive disorder (MDD) have lower expression levels of astrocyte markers and lower densities of astrocytes labeled for these markers, suggesting a loss of astrocytes in this mental illness.
Mounting evidence has shown that astrocytic dysfunction is involved in the progression of depression and AD. We herein review the current findings on the roles and mechanisms of astrocytes in the development of depression and AD, with an implication of potential therapeutic avenue for these diseases by targeting astrocytes.
Each year, more than 15,000 people in the United States are newly diagnosed with diffuse astrocytic and oligodendroglial tumors, including glioblastoma, the most common type of malignant primary brain tumor encountered by oncologists.1 The clinical care of people with these tumors is in the midst of a paradigm shift because of the evolving role ...
1 gru 2022 · Purinergic receptors at astrocytes modulate intracellular pathways relevant for the development of depression. The role of the astrocytic purinergic system in the pathophysiology of depression mainly consists of the regulation of neurotransmission, neuroinflammation, and synaptic plasticity.
